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Stevastelins, a novel group of immunosuppressants, inhibit 
dual-specificity protein phosphatases 
Takuya Hamaguchi l, Akira Masuda*, Tomio Merino* and Hiroyuki Osadal 
Background: Since the molecular target of the immunosuppressive reagents 
FK506 and cyclosporin A was revealed to be protein phosphatase PPPB 
(calcineurin), many researchers have been screening the protein phosphatase 
inhibitors from microbial metabolites to develop new immunosuppressive 
reagents. We isolated stevastelin B, which is composed of valine, threonine, 
serine and 3,5-dihydroxy-2,4-dimethyl stearic acid, and stevastelin A, which is a 
sulphonylated derivative of stevastelin B. To understand the action mechanism 
of stevastelins A and B, we synthesized a series of stevastelin derivatives and 
investigated their structure-activity relationships. 
Results: A series of stevastelin derivatives have been systematically 
synthesized. Stevastelin B inhibited gene expression that is dependent on inter- 
leukin-2 (IL-2) or IL-6 promoters in situ, but it had no inhibitory activity against 
any protein phosphatases in vitro. In contrast, stevastelin A, which is a sulpho- 
nylated derivative of stevastelin B, inhibited the phosphatase activity of a dual- 
specificity phosphatase, VHl -related human protein (VHR), in vitro, but it had 
no inhibitory activity against gene expression or cell-cycle progression in situ. 
Conclusions: Stevastelin B is a novel immunosuppressant. It inhibited IL-2 or 
IL-6 dependent gene expression but did not inhibit the phosphatase activity of 
calcineurin. The structure-activity relationships show that the acidic functional 
group on the threonine residue and the stearic acid moiety in the stevastelin 
molecule are important for inhibitory effects on the dephosphorylation activity of 
VHR in vitro. Stevastelin B might be sulphonylated or phosphorylated after 
incorporation into the target cell, and then it interacts with protein tyrosine 
phosphatases and regulates cell-cycle progression. 
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Introduction 
Cyclosporin A (&A) [I,21 and FK506 [3,4] are known to be 
immunosuppressive compounds that have similar inhi- 
bitory effects on T lymphocytes [5]. Both drugs bind to 
immunophilins, cyclophilin and FKBP, respectively, and 
inhibit the phosphatase activity of calcineurin (PPZB), 
which is a Ca*+-dependent and calmodulin-dependent 
serine/threonine phosphatase [6,7]. In addition, the drugs 
inhibit the transcription of the interleukin-2 (IL-Z) gene, 
which is essential for the immune response [8,9]. CsA and 
FK506 also inhibit cell-cycle progression at the Gl phase in 
normal human T lymphocytes [lO,ll]. To discover new 
immunosuppressive reagents from microbial metabolites, 
we have been screening new phosphatase inhibitors which 
directly inhibit the PPZB activity or other phosphatase 
activities. Protein phosphatases are grouped as protein 
serine/threonine phosphatases (PPases), protein tyrosine 
phosphatases (PTPases) and dual-specificity phosphatases 
(DSPases) [l&13]. It is known that protein phosphatases 
are involved in the process of cytokine signalling from the 
cell membrane to the nucleus of mammalian cells. In par- 
ticular, DSPases, including VHl-related human protein 
(VHR), cdc25, HVHl and 3CH134, are known to be 
involved in many aspects of cellular responses, such as cell- 
cycle progression [14,15], MAP kinase inactivation [16], and 
growth factor stimulation [17]. Thus, we have been screen- 
ing inhibitors from microbial metabolites against PPases 
(PPl and PPZB), a PTPase (CD45) and a DSPase (VHR). 
Recently, stevastelins were isolated by us from the cul- 
tured broth of Penidhn sp. NK374186 [l&19]. Stev- 
astelins are composed of valine, threonine, serine and a 
3,5-dihydroxy-2,4-dimethylstearic acid moiety (Fig. 1). 
They have growth-inhibition activities against OKT3- 
stimulated human T cell proliferation, but their biological 
properties have been unclear. 
Here, we report that some of the stevastelins inhibited 
the dephosphorylation activity of VHR, and some inhib- 
ited cell-cycle progression. To clarify the structure-activ- 
ity relationships of the stevastelins we prepared a series of 
stevastelin derivatives and evaluated their inhibitory 
activities both on protein phosphatases and on the cell 
cycle. We find that the functionality at the threonine 
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Structures of stevastelins. In stevastelins A3, 
83, C3, D3 and E3, cyclization occurred at 
the C-3 carbon of stearic acid (defined as 
‘ester position 3’). Other stevastelins had the 
‘ester position 5’. 
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residues of stevastelins is particularly important for their by esterilication. Stevastelins 35 and 39 have no long-chain 
inhibitory activities. aliphatic hydrocarbon group. 
Results 
Preparation of stevastelins 
Stevastelins A, B, A3, B3, C3, D3 and E3 (Fig. 1) were 
purified from the fermentation broth of Penicdhm sp. 
NK374186 as described previously [18,19]. Stevastelins H 
and P were obtained by acetylation and phosphorylation, 
respectively, of the threonine residue of stevastelin B 
(Fig. 2). Stevastelins 35 and 39 were synthesized using the 
general chemical methods summarized in Figure 3. Com- 
pound 1 was synthesized using the valine and threonine 
derivatives and coupling agents, and compound 2 was syn- 
thesized from 5hydroxypentanoic acid and 0-acetylserine 
Figure 2 
Immunosuppressive effects of stevastelins 
Stevastelins B, B3, C3 and E3 were originally discovered 
as inhibitors of the IL-Z and IL-6 promoter-dependent 
B-galactosidase gene expressions in Jurkat cells, and stev- 
astelins A, A3, and D3 were isolated as the congeners. The 
inhibitory effects of stevastelins on gene expression in 
Jurkat cells are summarized in Table 1. Stevastelins B, B3, 
C3 and E3 (B-type) have a free hydroxyl group in their 
threonine residues and showed inhibitory activities on 
gene expression. In contrast, stevastelins A, A3 and D3 (A- 
type), which have 0-sulphonylated threonine residues, did 
not show any inhibitory activities. 
(a) 
. 
Stevastelin H 
Stevastelin P 
Synthesis of stevastelins H and P. Reagents 
and conditions: (a) (CH,CO),O, pyridine, r. t.; 
(b) 1 H-tetrazole, N,N diethyl-1,5-dihydro- 
2,4,3-benzodioxaphosphepin-3-amine, 
CH,CI,, r.t., then H,O; and (c) m-chloro- 
perbenzoic acid (mCPBA), CH,CI,, -40°C. 
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Figure 3 
Synthesis of stevastelins 35 and 39. 
Reagents and conditions: (a) HOBt 
(1 -hydroxybenzotriazole hydrate), Et,N, EDC 
(l-(3-dimethylaminopropyl)-3-ethylcarbodi- 
imide), DMF, -20°C; (b) Pd-C, H,, EtOH, 
60°C; (c) HOBt, Et,N, EDC, DMF, -20°C; 
and (d) sulphur trioxide trimethylamine 
complex, DMF, 50°C. 
Stevastelin 35 Stevastelin 39 
To confirm the involvement of the hydroxyl group in the 
threonine residue in stevastelin B in the biological activity 
of the compound, we prepared stevastelins P and H which 
are 0-phosphorylated and 0-acetylated derivatives of 
stevastelin B, respectively. 0-Acetylation of the threonine 
residue in stevastelin H slightly reduced the inhibitory 
activities, and 0-phosphorylation of this residue (stev- 
astelin P) resulted in the loss of inhibitory activity in situ. 
The acidic functionality of the threonine residue may 
interfere with the membrane permeability of stevastelins. 
Two totally synthesized derivatives, stevastelins 35 and 39, 
that lack a long-chain aliphatic hydrocarbon group did not 
have inhibitory activities, regardless of the acidic function- 
ality of the threonine residue. Thus, both the free threo- 
nine hydroxyl group and a long-chain aliphatic hydrocarbon 
Table 1 
Inhibition of IL-2 and IL-6 promoter-dependent pgalactosidase 
gene expression by stevastelins. 
Activity [IC,, (FM)] 
Stevastelin Thr-OH IL-2* IL-6+ 
A sulfonyl >25 >25 
A3 sulfonyl >25 >25 
D3 sulfonyl >25 >25 
P phosphoryl >25 >25 
39 sulfonyl >25 >25 
H acetyl 11.5 5.7 
B free 4.6 3.1 
83 free 4.6 3.1 
c3 free 4.9 4.9 
E3 free 5.0 3.4 
35 free >25 >25 
Cyclosporin A 0.042 1.7 
*IL-2 promoter-dependent P-galactosidase gene expression was 
induced by ionomycin plus phorbol myristate acetate (PMA) for 5 h. 
+lL-6 promoter-dependent P-galactosidase gene expression was 
induced by lipopolysaccharide (LPS) for 4 h. 
group are required for the inhibitory activities against the 
promoter-dependent gene expression in sitzc. 
Inhibitory effects of stevastelins on protein phosphatase 
in vitro 
To clarify the molecular target for the inhibitory activity 
of stevastelin B, we investigated the inhibitory effects of 
stevastelins on protein phosphatases including PPl, 
PPZA, PPZB, CD45 and VHR. Interestingly, although 
stevastelins A, A3, and D3 had no inhibitory activity in 
situ, they had strong inhibitory activity against VHR in 
vitro (Table 2). As shown in Figure 4, the inhibition of the 
dephosphorylation activity of VHR by stevastelin 
A (IC,,=2.7 yM) was more potent than that by stev- 
astelins B (IC,,=19.8 PM), stevastelin 35 (IC&>lOOO PM) 
and stevastelin 39 (IC,, > 1000 FM). 
In contrast, stevastelin B, which caused strong inhibition 
in situ, was about sixfold less active in vitro than the ana- 
logues that had a modified threonine residue. The acidic 
functionalities of the threonine residues of stevastelins A 
(0-sulphonyl) and P (0-phosphoryl) were found to be 
essential for inhibitory activities towards VHR in vitro. 
Stevastelins A and A3 are cyclized at the ‘ester position 5’ 
and ‘ester position 3’ (Fig. l), respectively, which had no 
influence on the inhibitory activity. Stevastelins 35 and 
39, which have no stearic acid moiety, had no inhibitory 
activity both in situ and in vitro. Stevastelin P had weak 
inhibitory activity (IC,,= 0.61 FM) against CD45, but 
other stevastelin derivatives had no activities. 
Effects of stevagtelins on the cellular phosphoproteins of 
Ball-l cells 
Next, we investigated the effects of stevastelin deriva- 
tives on the tyrosine-phosphorylation level of cellular 
phosphoproteins in a human B cell leukemia cell line, 
Ball-l. Cell lysates prepared from Ball-l cells were treated 
with various compounds and analyzed by sodium dodecyl 
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Table 2 
Inhibitory potencies of stevastelins to protein phosphatases. 
Activity* [IC,&M)] 
Group Stevastelin VHR CD45 PPases+ 
A 2.7 >lOOO >lOOO 
A-type A3 3.6 >lOOO >lOOO 
potent D3 1.7 >lOOO >lOOO 
inhibitors P 4.0 160 >lOOO 
B 19.8 >lOOO >lOOO 
B-type B3 13.7 >lOOO >lOOO 
weak c3 16.0 >lOOO >lOOO 
inhibitors E3 13.6 >lOOO >lOOO 
H 24.0 >lOOO >lOOO 
Inactive 35 >lOOO >lOOO >lOOO 
inhibitors 39 >lOOO >lOOO >lOOO 
*Protein phosphatases were prepared as described in the Materials and methods section. Inhibitory activities of stevastelins against phosphatase 
activities to pNpp (PPl , PP2A, VHR), 32P-labelled casein (PPPB), and phosphotyrosine (CD45). ‘PPases represent the inhibitory effects of 
stevastelins. 
sulphate-polyacrylamide gel electrophoresis (SDS-PAGE). 
The phosphotyrosine level was analyzed by western blot- 
ting with an anti-phosphotyrosine antibody (Fig. 5). Stev- 
astelins A (lane 4) and P (lane 6) markedly increased the 
level of tyrosine phosphorylation of some cellular phos- 
phoproteins as did sodium orthovanadate (vanadate; 
lane 2) and RK-682 (lane 3). This showed that stevastelins 
A and P at high concentration inhibited cellular PTPases 
in vitro. In contrast, stevastelin B showed no inhibitory 
effect towards cellular PTPases in cell-free lysate even at 
high concentration (lane 5). 
Figure 4 
1 o-5 1 o-4 
Concentration (M) 
The effects of stevastelins on the dephosphorylation activity of 
GST-VHR. Inhibitory activity of stevastelin A (O), B (O), 35 (W) and 
39 (0). GST-VHR was prepared as described in the Materials and 
methods section. 
Effects of stevastelins on cell-cycle progression 
Immunosuppressants as well as protein-phosphatase inhi- 
bitors are known to interfere with the cell-cycle progression 
Figure 5 
M W  ‘(KDa) 
1 2 3 4 5 6 
71- 
36- 
The effects of phosphatase inhibitors on tyrosine phosphorylation in 
Ball-l cells. Protein was loaded on a gel (3 kg per lane) for western 
blotting with anti-phosphotyrosine antibody. Phosphatase inhibitors 
vanadate (460 FM, lane 2), RK-682 (230 )LM, lane 3), stevastelin A 
(340 FM, lane 4), stevastelin B (340 PM, lane 5) and stevastelin P 
(340 FM, lane 6) were added to Ball-l cell lysates. Lane 1 is the 
control without inhibitor. 
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Figure 6 
The influence of stevastelins on the cell-cycle 
progression of the tsFT210 cell line. 
(a) tsFT210 cells were cultured at 32°C for 
17 h, (b) raised to 39°C for 17 h and (c) then 
lowered to 32°C for 4 h after adding 
inhibitors. Cells were treated with 
(d) vanadate (165 PM), (e) stevastelin A 
(40 PM), and (f) stevastelin B (45 PM), and 
analyzed by flow cytometry. 
DNA content 
LL- 
DNA content 
A&L&-l 
DNA content 
of mammalian cells. We therefore investigated the inhibi- 
tory effects of stevastelins on the cell-cycle progression of 
tsFTZ10 cells. (The tsFTZl0 cell is a temperature-sensi- 
tive cdcZ mutant of the mammary carcinoma cell line, 
FM3A.) The cells grew normally at the permissive temper- 
ature (32°C; Fig. 6a) but were arrested in the G2 phase at 
the nonpermissive temperature (39°C; Fig. 6b). When the 
temperature was lowered to 32°C after incubation at 39°C 
for 17 h, the cell cycle progressed into the Gl phase 
(Fig. 6~). As shown in Figure 6, stevastelin B (Fig. 6f) 
inhibited the cell-cycle transition from GZ/M to Gl phase 
like vanadate (Fig. 6d), but stevastelin A had no inhibitory 
effect (Fig. 6e). 
Discussion 
FK506 and CsA are valuable reagents not only as immuno- 
suppressants but also as biochemical tools with which to 
investigate the signal transduction mechanism. It is known 
that FK506 and CsA bind to immunophilins (FKBPs and 
cyclophilins) first, then respective FK506-FKBP and 
CsA-cyclophilin complexes inhibit the serine/threonine 
phosphatase activity of calcineurin [8,20], and finally, they 
inhibit the nuclear transport of a cytoplasmic subunit of 
NFAT in human T cells [Zl]. These findings stimulated 
the exploitation of new immunosuppressive compounds 
from microbial metabolites. 
Other specific phosphatase inhibitors are also useful for 
investigating the signal transduction mechanism in mam- 
malian cells. Indeed, PPase inhibitors, okadaic acid [ZZ] 
and tautomycin [23] were used to elucidate the physiologi- 
cal role of serine/threonine phosphorylation in signal trans- 
duction. In contrast, only vanadate [24], phenylarsine oxide 
(PAO) [ZS], dephostatin [26] and RK-682 [14] have been 
demonstrated to be PTPase inhibitors or dual-specificity 
phosphatase inhibitors. We have established two bioassay 
methods to find new immunosuppressants and have 
started screening for inhibitors of IL-Z and IL-6 dependent 
gene expression in Jurkat cells and for inhibitors of protein 
phosphatases. During screening, stevastelin B was origi- 
nally isolated as an inhibitor of the IL-Z or IL-6 dependent 
gene expression in Jurkat cells [18], but at that time, stev- 
astelin A was only recognized as an inactive congener of 
stevastelin B. Now, we have shown that stevastelin A is a 
phosphatase inhibitor; so, we examined the biological prop- 
erties and structure-activity relationships of stevastelin 
derivatives in this study. 
B-type stevastelins (B, B3, C3 and E3) were more potent 
inhibitors of IL-Z and IL-6 dependent gene expression 
than A-type stevastelins (A, A3, and D3) in Jurkat cells. 
The two types only differ structurally by the acidic func- 
tional group at the threonine residue. To confirm whether 
the functional group at the threonine residue was involved 
in the inhibitory action, we synthesized stevastelins H and 
P from stevastelin B. As a result, it was revealed that the 
phosphorylation of the hydroxyl group at the threonine 
residue in stevastelin B may interfere with the membrane 
permeability and resulted in the loss of its immunosup- 
pressive activity in situ (Table 1). In contrast, stevastelin 
derivatives that possessed an acidic functional group on 
the threonine residue, and a stearic acid moiety in their 
structures showed strong inhibition of VHR in aitro. 
These data suggest that A-type stevastelins have poor 
membrane permeability due to the acidic functionality of 
the threonine residue, but B-type stevastelins easily per- 
meate the cell membrane. In particular, a long-chain 
aliphatic hydrocarbon group was important because the 
totally synthesized compounds, stevastelins 35 and 39, 
that lacked an aliphatic hydrocarbon chain did not have 
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Figure 7 
Stevastelin A : R=SO,H 
B: R=H 
P: R=PO,H 
Tentative model for the inhibition of 
phosphatases by stevastelins. Stevastelin A is 
an inhibitor of VHR, but it may hardly 
permeate the cell membrane. In contrast, 
stevastelin B may permeate the cell 
membrane and arrest cell cycle at the G2 
phase. Stevastelin B is converted to an 
activated form such as stevastelin P by 
cellular enzyme(s) and interacts with VHR or 
unidentified PTPases, which regulate the 
G2/M transition. 
any inhibitory activities in vitro or in &JO, regardless of the 
acidic functionality of the threonine residue. 
Next, we investigated the inhibitory effect of stevastelins 
on the cell cycle of tsFT210 cells. Because tsFT210 cells 
are temperature-sensitive mutants of cdc2 kinase [27], the 
cells are suitable for the cell-cycle analysis of GZ/M transi- 
tion [28]. Stevastelin A had an inhibitory activity towards 
VHR in vitro (Fig. 4) but not towards the cell-cycle pro- 
gression of tsFT’210 cells (Fig. 6e) because it has poor 
membrane permeability. In contrast, stevastelin B had 
less activity than stevastelin A in vitro, but it inhibited the 
cell cycle at the GZ/M transition (Fig. 6f). These observa- 
tions suggest that stevastelin B may be phosphorylated or 
sulphonylated by cellular enzyme(s) after incorporation 
into the target cells and converted to a form such as stev- 
astelin P or A that is active against phosphatases (Fig. 7). 
Consequently, the reason why stevastelin H has less of an 
effect than stevastelin B is presumably because the acetyl 
group at the threonine residue of stevastelin H interferes 
with its in situ conversion into stevastelin A or P. To inves- 
tigate this conversion by any cellular serine/threonine 
kinases, we added stevastelin B to Ball-l intact cells or 
cell lysates, which were labelled with 32P-ATP, and ana- 
lyzed the existence of stevastelin P in the cytosol fraction 
by thin layer chromatography or autoradiography. We 
could not detect either stevastelins B or P, however, 
because a detectable amount of stevastelin B was cyto- 
toxic to Ball-l intact cells. According to the data shown in 
Figure 5, it may take time to convert stevastelin B to an 
active form such as stevastelin P or A in the cell lysate. 
The acid functionality group at the threonine residue of 
stevastelins might be needed for inhibitory activity not 
only towards VHR but also towards cellular PTPase of 
Ball-l. It is possible that stevastelin B binds to 
immunophilins and inhibits calcineurin activity in situ. 
This possibility was excluded, however, by results from 
experiments using the yeast Saccharomyces cermisiae [29]. 
FK506 and CsA recovered the growth of S. cerevisjae on an 
agar plate containing a high concentration of Ca*+, but all 
stevastelin derivatives had no effect on the PPZB-depen- 
dent growth control in S. cerevisiae (data not shown). 
Stevastelins are considered to be a novel group of 
immunosuppressants because their immunosuppressive 
activity is not due to the inhibition of calcineurin. Thus, 
stevastelins are potentially useful as bioprobes to eluci- 
date a new signal transduction pathway in eukaryotic cells. 
Significance 
We have isolated stevastelins A and B from fungal 
metabolites. To understand their molecular action, a 
series of derivatives were systematically synthesized 
and their structure-biological activity relationships 
were investigated. 
Stevastelin B, which was originally isolated as an 
inhibitor of IL-2 and IL-6 dependent gene expression, 
did not inhibit calcineurin in yeast or any protein phos- 
phatase activities in vitro. Conversely, stevastelin A, a 
sulphonylated derivative of stevastelin B, potently inhib- 
ited the activity of a dual-specificity phosphatase, VHR, 
in vitro but did not show any inhibitory effects in vivo. 
According to the structure-biological activity relation- 
ships, it is suggested that the acidic functional group on the 
threonine residue and the steak acid moiety are impor- 
tant for the inhibitory action of stevastelins on VHR 
in vitro. The acidic functional group on the threonine 
residue in the stevastelin molecule may interfere with per- 
meation of the cell membrane. Thus, stevastelin B is con- 
sidered to be phosphorylated by cellular enzyme(s) and 
converted to stevastelins A or P, which have an 
inhibitory effect on cellular protein phosphatases. These 
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findings give a clue to understanding the cause of differ- 
ential activity among stevastelin derivatives and suggest 
that a dual-specificity phosphatase could be a relevant 
molecular target for immunosuppressive activity. 
Materials and methods 
Synthesis of stevastelins H and P 
Stevastelin B (42.6 mg, 0.065 mmol) was dissolved in pyridine contain- 
ing acetic anhydride (30.7 ul, 0.325 mmol). The reaction mixture was 
stirred at room temperature for 20 h and concentrated. The residue 
was purified by silica gel column chromatography to give stevastelin H 
(36.0 mg, 79% yield). 
Stevastelin P was obtained by phosphorylation of the threonine residue 
of stevastelin B. Stevastelin B (61.2 mg, 0.093 mmol) and 1 H-tetrazole 
(32.6 mg, 0.465 mmol) were combined and dissolved in CHzCI, (2 ml). 
N,/V-diethyl-l,5-dihydro-2,4,3-benzodioxaphosphepin-3-amine (24.1 ~1, 
0.1 12 mmol) was added, and the reaction mixture was stirred at room 
temperature for 30min under an argon atmosphere. Then, more 
N,N-diethyl-1,5-dihydro-2,3,4 benzodioxaphosphepin-3-amine (12.0 )*I, 
0.056 mmol) was added. After a further 20 min reaction under the same 
condition, Hz0 (50~1) was added and the reaction mixture was stirred 
for 10 min. The reaction mixture was cooled at -40°C 3-chloroperben- 
zoic acid (140mg, 0.81 1 mmol) was added, and it was stirred at room 
temperature for 1 Omin. Na,S,O, (1 go/,, w/v) was added to the mixture, 
which was then extracted with ethyl acetate. The organic layer was 
washed successively with a saturated NaCl solution and an aqueous 
NaHCO, solution, dried over Na,SO,, and concentrated on a rotary 
evaporator. The residue was purified by silica gel column chromatogra- 
phy to give the desired product (39.4mg, 51% yield). The product 
(29.1 mg, 0.035 mmol) was dissolved in 80% aqueous EtOH (5ml), 
10% palladium on charcoal (lO.Omg) was added, and it was 
hydrogenolyzed for 40min. The reaction mixture was filtered through 
Celite. Concentrated ammonia. was added to the filtrate, and the resul- 
tant mixture was concentrated. The residue was dissolved in Hz0 (1 ml) 
and lyophilized to give stevastelin P ammonium salt (25.9 mg, 96% yield). 
Synthesis of stevastelins 35 and 39 
Compounds 1 (1.149, 2.37 mmol) and 2 (710 mg, 2.04mmol) were 
combined and dissolved in N,N-dimethylformamide (DMF, 20 ml). 
1 -Hydroxybenzotriazole hydrate (HOBt; 331 mg, 2.45 mmol), triethyl- 
amine (285.2 ~1, 2.04 mmol) and 1-(3-dimethylaminopropyl)-3-ethyl- 
carbodiimide (EDC; 783.6 my, 4.09 mmol) were added at -20°C and 
stirred for 24 h at room temperature. The reaction mixture was concen- 
trated in vacua and extracted with ethyl acetate. The organic layer was 
washed successively with 5% (w/v) citric acid, saturated NaCl solution, 
and concentrated on a rotary evaporator. The residue was purified by 
silica gel column chromatography to give compound 3 (1.509, 99% 
yield). The product 3 (1.5Og 2.07 mmol) was dissolved in EtOH 
(20ml), 10% palladium on charcoal (160mg) was added and the 
mixture hydrogenolyzed at 60°C for 3.5 h. The reaction mixture was fil- 
tered through Celite and concentrated. Syrup (612 mg) was dissolved 
in CHzCI,, trifluoroacetic acid (TFA; 2 ml) was added and it was stirred 
for 1 h at room temperature. The reaction mixture was concentrated in 
vacua with toluene to give cornpound 4 (600 mg, 55% yield). 
The product 4 (410mg, 0.77 mmol) dissolved in DMF (150 ml) was 
added to 1 -hydroxybenzotriazole hydrate (147.2 mg, 1.08 mmol), tri- 
ethylamine (102.7 )*I, 0.73 mmol) and 1-(3-dimethylaminopropyl)-3-ethyl- 
carbodiimide (209.0 mg, 1.09 mmol) at -20°C and then stirred for 72 h 
at room temperature. The reaction mixture was concentrated in vacua 
and extracted with ethyl acetate. The organic layer was washed succes- 
sively with 5% (w/v) citric acid, a saturated NaCl solution, and concen- 
trated on a rotary evaporator to give stevastelin 35 (95 mg, 28% yield). 
Stevastelin 35 (6.2 mg, 0.014 mmol) was suspended in DMF, treated 
with sulphur trioxide trimethylamine complex (8.0 mg, 0.053 mmol) and 
stirred for 1 h at 50%. After removing the solvent in vacua, the residue 
was purified by silica gel column chromatography to give stevastelin 39 
(8.3 mg, 1 OOo/, yield). 
Cell cultufe 
A human B cell leukemia cell line, Ball-l, was obtained from Cell Bank 
(RIKEN) and maintained in a humidified atmosphere of 5% CO, and 
95% air at 37°C in RPMI-1640 medium supplemented with 10% fetal 
bovine serum (Gibco). A temperature-sensitive (ts) cdc2 mutant of the 
mammary carcinoma cell line, FM3A, tsFT210 cell [27], was obtained 
from F Hanaoka (RIKEN) and cultured at 32% in RPMI-1640 medium 
supplemented with 10% calf serum (Hyclone). 
Immunosuppressive activity 
IL-2 promoter-dependent expression was measured by a P-galactosi- 
dase reporter gene using the Jurkat cell line, NFIL-286.1 [9]. A cell line 
for measuring IL-6 promoter-dependent expression was established in 
this study. In brief, human IL-6 promoter segment (1.3 Kb DNA frag- 
ment between Barn Hl and Xhol restriction sites) was connected to 
bacterial p-galactosidase gene and transferred to the mouse 
macrophage cell line, J774.1 1301. Transfectants were selected by 
their G418 resistance. Expression of 8-galactosidase gene of these 
clones was induced by 1 pg ml-’ lipopolysaccharide (LPS). For assay, 
the inducer and sample were simultaneously added to cell cultures, 
and after 4 hours, 8-galactosidase activity was measured as described 
previously [9]. 
Phosphatase assay 
PPl and PP2A were purchased from Upstate Biotechnology Incorpo- 
rated (Lake Placid, NY, USA.). Dephosphorylation of p-nitro- 
phenylphosphate (pNpp) by PPl and PP2A was measured in an assay 
buffer containing 20 mM MOPS (pH 7.5), 60 mM P-mercaptoethanol, 
0.1 M  NaCI, 1 mg ml-’ bovine serum albumin and 50 %  (v/v) glycerol. 
PP2B (calcineurin) was partially purified from Saccharomyces cere- 
visiae [31]. Phosphatase activity of PP2B to the 32P-casein substrate 
was measured as described previously [29]. Glutathionine-S-trans- 
ferase (GST)-VHR fusion protein (VHR) was prepared as described 
[32]. Bacterially expressed GST-VHR (1 ug ml-l) was incubated at 
37% for 30 min with 10 mM pNpp in an assay buffer containing 25 mM 
MOPS (pH 6.5), 5mM EDTA, and 1 mM dithiothreitol (100 ul final 
volume). A CD45 fraction was prepared from Ball-l cells by the 
method described [33], and its PTPase activity to phosphotyrosine 
was measured by calorimetric assay 1341. 
Cell cycle assay 
The general procedure of cell-cycle analysis was previously reported 
[28]. Briefly, tsFT210 cells were cultured in a 12-well plate at a con- 
centration of 2 x 1 O5 cells per well with 1 ml of RPMI-1640 medium 
supplemented with 10% fetal bovine serum at 32% for 1 day. To test 
G2/M to Gl transition, cells were cultured at 39% for 17 h, and then 
the temperature was lowered to 32’C for 4 h after adding the inhibitors. 
The cells were then washed with phosphate buffered saline (PBS), 
stained with propidium iodide (Sigma) and analyzed by flow cytometry 
(Coulter, Epics Profile II, Hialeah, FL, USA). 
lmmunoblotting 
Ball-l cell lysates (4OOkg ml-l) were treated with phosphatase 
inhibitors for 1 h at 37°C. The lysates (3 pg protein per lane) were sub- 
jected to 1 Oo/, SDS PAGE, electrophoretically transferred to a nitrocel- 
lulose membrane, and incubated for 1 h with a monoclonal antibody to 
phosphotyrosine (1 G2, Chemicon International Inc., Temecula, CA, 
USA). The membrane was incubated with 0.5 ug ml-’ of horseradish 
peroxidase conjugated anti-mouse IgG (Amersham, UK) and visualized 
with a chemiluminescence system (ECL, Amersham). 
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